€
3. 56
+0.02
+0.4237%
€
117.61M Market Cap
- P/E Ratio
- Div Yield
20 Volume
0 Eps
€ 3.54
Previous Close Want to track 9Y4 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Ryvu Therapeutics S.A. (9Y4) Statistics
Valuation metrics
Market Cap 117.61M
Enterprise value 33.05M
Trailing P/E (ttm) -1.04
Forward P/E -
PEG ratio -
Price/Sales (ttm) 1.51
Price/Book (mrq) 1.62
Enterprise Value/Revenue 0.42
Enterprise Value/EBITDA -0.32
Overview
Shares outstanding 23.12M
Float 17.94M
Shares short -
% Held by insiders 0.35%
% Held by institutions 0.22%
Average volume (10 days) 108
Average volume (90 days) 108
Price summary
52-Week low 3.19
52-Week high 7.75
Beta 0.53
50-Day moving average 5.93
200-Day moving average 6.34
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 30 Sep 2025
Profitability
Profit margin -1.15%
Operating margin -1.38%
Operational effectiveness
Return on assets -0.2%
Return on equity -0.98%
Income Statement
Revenue (ttm) 77.97M
Revenue per share (ttm) 3.37
Quarterly revenue growth (yoy) -0.1%
Gross profit (ttm) 58.39M
EBITDA -20.6M
Net income to common (ttm) -111.44M
Diluted EPS (ttm) -1.03
Quarterly earnings growth (yoy) 3.2%
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) -
Total debt (mrq) 70.54M
Total Debt/Equity (mrq) 178.14
Current ratio (mrq) 2.26%
Book value per share (mrq) 3.08
Cash Flow
Cash flow statement -139.89M
Levered free cash flow (LFCF) -19.31M
